Agenus Inc. (AGEN) – What Are Investment Firms Saying About This Stock?

Agenus Inc. (NASDAQ:AGEN) has earned a consensus rating of “Moderate Buy” from the six analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $24.50.

A number of brokerages have commented on AGEN. B. Riley Financial reaffirmed a “buy” rating and issued a $14.00 price objective (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Wall Street Zen lowered Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target (down from $30.00) on shares of Agenus in a research note on Tuesday, August 11th. Chardan Capital reaffirmed a “buy” rating and set a $40.00 price objective on shares of Agenus in a research report on Monday, October 5th. Finally, Weiss Ratings upgraded shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday.

Institutional Trading of Agenus

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Redwood Family Wealth LLC bought a new position in Agenus in the fourth quarter valued at approximately $44,000. Ovata Capital Management Ltd bought a new stake in Agenus during the fourth quarter worth $97,000. Everhart Financial Group Inc. bought a new stake in Agenus during the third quarter worth $100,000. Bank of New York Mellon Corp bought a new stake in Agenus during the second quarter worth $311,000. Finally, Bank of America Corp DE boosted its holdings in shares of Agenus by 796.7% in the 1st quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock valued at $397,000 after purchasing an additional 105,536 shares in the last quarter. Institutional investors own 61.46% of the company’s stock.

Agenus Stock Down 3.1%

Shares of AGEN stock opened at $7.43 on Tuesday. Agenus has a 12-month low of $2.71 and a 12-month high of $10.31. The company has a market capitalization of $335.55 million, a PE ratio of 2.88 and a beta of 1.31. The firm has a 50 day moving average price of $7.83 and a two-hundred day moving average price of $5.33.

Agenus (NASDAQ:AGEN) last posted its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). The firm had revenue of $34.52 million during the quarter, compared to analyst estimates of $34.00 million. Agenus had a net margin of 69.33% and a negative return on equity of 47.68%. As a group, research analysts expect that Agenus will post -0.30 EPS for the current year.

About Agenus

Agenus Inc (NASDAQ: AGEN) is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination.

Agenus’ pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers.